Chinese Companies in European Patent Litigation

​
September 30, 2026

The European front in global patent disputes

This opening article examines Europe’s growing role in the global patent strategies of Chinese companies, with particular emphasis on recent UPC cases involving Chinese parties as claimants and defendants, including disputes between Chinese competitors. It is the first in a series exploring the practical implications for Chinese businesses of enforcing European patents and defending against patent claims in Europe.

Chinese companies’ rapidly growing investment in European patents is changing both their opportunities and their exposure in European patent litigation. Of the 201,974 patent applications received by the EPO in 2025, 10.9% originated from the People’s Republic of China, moving China ahead of Japan (10.5%) and into the top three countries of origin for the first time.1 This growth is expanding the pool of European rights available to Chinese businesses for enforcement, while their increasing commercial presence in Europe leaves them more exposed to competing portfolios. European patent strategy is therefore becoming an increasingly important component of the global portfolio management, licensing and litigation strategies of Chinese businesses.

Chinese companies become major players in European patent litigation

Our earlier article analysed the growing presence of Chinese parties at the UPC; some of its key findings are briefly summarised here.2 It found that many Chinese defendants operated in sectors characterised by intensive patent licensing and enforcement activity, particularly telecommunications, consumer electronics and connected devices, and identified repeated enforcement campaigns against companies including Xiaomi, Transsion, Huawei, OPPO, vivo, BYD, TCL and Hisense. Increasingly, however, Chinese companies are also substantial European patent owners with their own enforcement programmes. Our review of the UPC’s public register identified 97 infringement actions filed in 2025 involving at least one Chinese party, approximately 38% of the 253 visible actions reviewed. Eighty-four involved a Chinese defendant, twenty a Chinese claimant, and seven involved Chinese parties on both sides.2 Together, these figures reflect a broader shift: Chinese companies continue to face patent actions in Europe, but are increasingly turning to European courts to enforce their own patent portfolios.

Enforcing patent rights through the Unified Patent Court

JingAo Solar v Chint/Astronergy, UPC_CFI_425/2024, illustrates affirmative UPC enforcement by a Chinese patent owner against a Chinese competitor. The case was handled at first instance by the Munich Local Division and concerned a solar-cell patent. The Court found infringement, rejected the counterclaim for revocation and granted injunctive and ancillary relief concerning Germany, France, Italy and the Netherlands.3 The parties reached a global settlement.4 The case shows a Chinese patent owner obtaining substantive multi-country relief through a German UPC division.

The more recent Yangtze Memory Technologies’ global enforcement campaign against US-based Micron concerning NAND technology demonstrates how national and UPC proceedings can be coordinated. On 18 September 2026, the Munich Regional Court granted YMTC two first-instance injunctions based on German utility models.5 In parallel, YMTC is asserting three European patents against Micron before the UPC’s Düsseldorf Local Division, alongside proceedings in the United Kingdom, the United States and China. [5] [6] The campaign shows how a Chinese patent owner can combine fast national remedies with the prospect of broader UPC relief to create leverage in a strategically important global technology dispute.

Trade fairs, evidence gathering and procedural risk

The dispute between Chinese robot-vacuum manufacturers Ecovacs and Roborock highlights both litigation between Chinese competitors and the procedural opportunities and risks associated with European trade fairs. Their contest now comprises six UPC infringement actions, alongside litigation in Germany, China and the United States.7 In March 2026, the Court of Appeal upheld the revocation of an ex parte inspection and evidence-preservation order that Ecovacs had obtained in relation to Roborock products displayed at the IFA trade fair in Berlin. The Court emphasised the applicant’s heightened duty to disclose fully and accurately all material facts relevant to necessity and proportionality.8 The dispute illustrates the risks surrounding European product launches and trade fairs, including evidence gathering and urgent procedural measures. These opportunities and risks will be examined in a forthcoming article in this series.

Abbott v Sinocare, UPC_CFI_624/2025 and UPC_CoA_899/2025, illustrates the exposure that can arise from plans directed at European markets. On 30 March 2026, the Court of Appeal rejected Sinocare’s appeal and left in place a preliminary injunction concerning a Unitary Patent. Importantly, the Court held that manufacturing and preparing products in China for sale in UPC contracting states could create the requisite likelihood of damage within UPC territory, even if the acts causing that damage occurred outside it. The decision demonstrates how European distribution plans and market-facing partnerships can expose Chinese companies to the UPC’s reach. 9

Strategic considerations for Chinese companies operating in Europe

These cases show Chinese businesses becoming increasingly active participants in the European patent system, with their portfolios, products, subsidiaries and commercial relationships placing them on either side of fast-moving disputes. The forthcoming articles will examine the practical decisions arising before and during such disputes: when to choose the UPC rather than a German national court; how service of process in China and security for costs can shape timing and economics; how to prepare for and respond to patent disputes arising at European trade fairs; when European subsidiaries, authorised representatives, distributors or other supply-chain participants may provide a jurisdictional link or become enforcement targets; and how Chinese groups should prepare for the developing cross-border reach of European courts.

Across these topics, the central theme will be the same: increased patent ownership creates enforcement opportunities, but growing commercial integration with Europe also creates exposure. Chinese companies that align portfolio management, licensing, product launches, corporate structures and litigation readiness early will be better placed to use Europe proactively rather than respond only after an action has defined the battlefield.

Author: Sebastian Fuchs - Partner, Rechtsanwalt, UPC Representative
‍

The Latest Thought Leadership pieces in the Content Hub

AI and Bitstreams at the Core of China’s Patent Update
May 28, 2025
On April 30, 2025, the China National Intellectual Property Administration (CNIPA) released a draft amendment of the Patent Examination Guidelines (for public comment), proposing further revisions to...
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​